Pediatric Drugs

, Volume 6, Issue 5, pp 289–301

Treatment of Ocular Inflammation in Children

Therapy In Practice


Ocular inflammation in children is of substantial epidemiologic importance, particularly since uveitis in children produces more vision loss than it does in adults. This is partially because there is a higher rate of posterior uveitis in childhood uveitis than in the adult population.

Treatment of ocular inflammation in children, ranging from conjunctivitis to keratitis to scleritis to uveitis, depends, of course, on whether or not the problem is microbial, traumatic, malignant, or autoimmune. Most of the cases that are vision threatening are autoimmune, and corticosteroids represent the mainstay of short-term therapy. However, abundant evidence exists which shows that all too often imprudent, prolonged use of corticosteroids is employed with resultant iatrogenic damage, including cataract, glaucoma, and secondary infection.

A new paradigm for treating ocular inflammation (uveitis in particular) is espoused in this article. It is based on a limited tolerance to corticosteroid use and a more proactive approach to corticosteroid-sparing immunomodulatory therapy in an effort to induce a durable remission off all corticosteroids.


  1. 1.
    Leibowitz HM. Primary care: the red eye. N Engl J Med 2000; 343: 345–51PubMedCrossRefGoogle Scholar
  2. 2.
    Bohigian GM, Valluri S. Handbook of ocular infections, inflammation and external diseases. 3rd ed. Thorefore (NJ): Slack Inc., 2000: 31–71Google Scholar
  3. 3.
    D’Aversa G, Stern GA, Driebe Jr WT. Diagnosis and successful medical treatment of Acanthamoeba keratitis. Arch Ophthalmol 1995 Sep; 113(9): 1120–3PubMedCrossRefGoogle Scholar
  4. 4.
    Beigi B, Algawi K, Foley-Nolan A, et al. Herpes simplex keratitis in children. Br J Ophthalmol 1994; 78: 458–60PubMedCrossRefGoogle Scholar
  5. 5.
    Samson CM, Ekong A, Foster CS. Uveitis in children: diagnosis and management. Int Ophthalmol Clin 2001; 41: 199–216PubMedCrossRefGoogle Scholar
  6. 6.
    Kanski JJ, Shun-Shun GA. Systemic uveitis syndromes in childhood: an analysis of 340 cases. Ophthalmology 1991; 91: 1247–52Google Scholar
  7. 7.
    Cunningham Jr ET. Uveitis in children. Ocul Immunol Inflamm 2000; 8: 251–61PubMedCrossRefGoogle Scholar
  8. 8.
    Okada AA, Foster CS. Posterior uveitis in the pediatric population. Int Ophthalmol Clin 1992; 32: 121–52PubMedCrossRefGoogle Scholar
  9. 9.
    Foster CS, Vitale AT. Diagnosis and treatment of uveitis. Philadelphia (PA): WB Saunders, 2002Google Scholar
  10. 10.
    Andersson Gare B. Incidence and prevalence of juvenile chronic arthritis: a population survey. Ann Rheum Dis 1987; 46: 277–81PubMedCrossRefGoogle Scholar
  11. 11.
    Kanski JJ. Juvenile arthritis and uveitis. Surv Ophthalmol 1990; 34: 253–67PubMedCrossRefGoogle Scholar
  12. 12.
    Malagon C. The iridocyclitis of early onset pauciarticular juvenile rheumatoid arthritis: outcome in immunogenetically characterized patients. J Rheumatol 1992; 19: 160–3PubMedGoogle Scholar
  13. 13.
    Nguyen QD, Foster CS. Saving the vision of children with juvenile rheumatoid arthritis: associated uveitis. JAMA 1998; 280: 1133–4PubMedCrossRefGoogle Scholar
  14. 14.
    Weiss AH. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. N Engl J Med 1998; 133: 266–8Google Scholar
  15. 15.
    Shetty AK, Zganjar BE, Ellis GS, et al. Low-dose methotrexate in the treatment of juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 1999; 36: 125–8PubMedGoogle Scholar
  16. 16.
    Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 1043–9PubMedCrossRefGoogle Scholar
  17. 17.
    Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis. Ophthalmology 2001; 108: 1134–9PubMedCrossRefGoogle Scholar
  18. 18.
    Akpek EK. Bechet’s disease [online]. Available from URL: [Accessed 2004 Jun 20]
  19. 19.
    Karma A, Seppala I, Mikkila H, et al. Diagnosis and clinical characteristics of ocular lyme borreliosis. Am J Ophthalmol 1995; 119: 127–35PubMedGoogle Scholar
  20. 20.
    Breeveld J, Kuiper H, Spanjaard L, et al. Uveitis and lyme borreliosis. Br J Ophthalmol 1993; 77: 480–1PubMedCrossRefGoogle Scholar
  21. 21.
    Ormerod LD, Dailey JP. Ocular manifestations of cat-scratch disease. Curr Opin Ophthalmol 1999; 10: 209–16PubMedCrossRefGoogle Scholar
  22. 22.
    Smith JR, Rosenbaum JT. Management of immune-mediated uveitis. Biodrugs 2000; 13: 9–20PubMedCrossRefGoogle Scholar
  23. 23.
    Giles CL. Pediatric intermediate uveitis. J Pediatr Ophthalmol Strabismus 1989; 26: 136–9PubMedGoogle Scholar
  24. 24.
    Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995; 120: 55–64PubMedGoogle Scholar
  25. 25.
    Stanbury RM, Graham EM. Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998; 82: 704–8PubMedCrossRefGoogle Scholar
  26. 26.
    Lai HC, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342: 851–9PubMedCrossRefGoogle Scholar
  27. 27.
    Ferraris JR, Pasqualini T, Legal S, et al. Effect of deflazacort methylprednisone on growth, body composition, lipid profile and bone mass after renal transplantation: the Deflazacort Study Group. Pediatr Nephrol 2000; 14: 682–8PubMedCrossRefGoogle Scholar
  28. 28.
    Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492–513PubMedCrossRefGoogle Scholar
  29. 29.
    Lindsley CB, Warady BA. Nonsteroidal anti-inflammatory drugs: renal toxicity. Clin Pediatr (Phila) 1990; 29: 10–3CrossRefGoogle Scholar
  30. 30.
    Shupack JL, Webster OF. Pancytopenia following low-dose methotrexate therapy in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145–6CrossRefGoogle Scholar
  31. 31.
    Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991; 35: 369–85PubMedCrossRefGoogle Scholar
  32. 32.
    Ohosone Y, Okano Y, Kameda H, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997; 24: 2299–303PubMedGoogle Scholar
  33. 33.
    Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology 1993; 100: 809–17PubMedGoogle Scholar
  34. 34.
    Kader HA, Wenner Jr WJ, Telega GW, et al. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000; 30: 409–13PubMedCrossRefGoogle Scholar
  35. 35.
    Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003 May; 110(5): 1061–5PubMedCrossRefGoogle Scholar
  36. 36.
    Virga M, Carter JE, Lirenman DS. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplant 2001; 5: 293–6CrossRefGoogle Scholar
  37. 37.
    Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory noninfectious childhood uveitis. Br J Ophthalmol 1998; 82: 737–42PubMedCrossRefGoogle Scholar
  38. 38.
    Mochizuchi M, Masuda K, Tuyoshi S, et al. A clinical trial of FK 506 in refractory uveitis. Am J Ophthalmol 1993; 115: 763–9Google Scholar
  39. 39.
    Martin DF, DeBarge LR, Nussenblatt RB, et al. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922–7PubMedGoogle Scholar
  40. 40.
    Latta K, von Schnakenburg C, Ehrich J. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001; 16(3): 271–82PubMedCrossRefGoogle Scholar
  41. 41.
    Guesry P, Lenoir G, Broyer M. Gonadal effect of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92: 299–303PubMedCrossRefGoogle Scholar
  42. 42.
    Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620–6PubMedCrossRefGoogle Scholar
  43. 43.
    Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis. Ophthalmology 2002; 109: 137–41PubMedCrossRefGoogle Scholar
  44. 44.
    Lowell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763–9CrossRefGoogle Scholar
  45. 45.
    Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411–5PubMedCrossRefGoogle Scholar
  46. 46.
    Papaliodis GN, Chu D, Foster CS. Treatment of inflammatory disorders with daclizumab. Ophthalmology 2003 Apr; 110(4): 786–9PubMedCrossRefGoogle Scholar
  47. 47.
    Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252–7PubMedCrossRefGoogle Scholar
  48. 48.
    El-Shabrawi Y, Graz JH. Anti-TNF-α therapy with infliximab in the treatment of HLA-B27 associated acute anterior uveitis: a 1-year follow-up [abstract]. Arthritis Rheum 2001; 44: S123Google Scholar
  49. 49.
    Banares A, Abasolo L, Macarron P, et al. Treatment of refractory posterior uveitis with anti-TNF-α infliximab [abstract]. Arthritis Rheum 2001; 44: S90Google Scholar
  50. 50.
    Honkanen V, Lappi M, Koskinen L, et al. Infliximab treatment in the refractory chronic uveitis of juvenile idiopathic arthritis (JIA) [abstract]. Arthritis Rheum 2001; 44: S292Google Scholar
  51. 51.
    Foster CS, Tufail F, Waheed KW, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003; 121: 437–40PubMedCrossRefGoogle Scholar
  52. 52.
    Ekberg H, Backman L, Tufveson G, et al. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation: No. 14874 and No. 14393 Zenapax Study Groups. Transplant Proc 1999; 31: 267–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Harvard Medical SchoolMassachusetts Eye and Ear InfirmaryBostonUSA

Personalised recommendations